On the way to find a cure: Purging latent HIV‐1 reservoirs

[1]  K. Hynynen,et al.  Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound , 2017, Neuropharmacology.

[2]  M. Carrillo,et al.  Chimeric antigen receptor engineered stem cells: a novel HIV therapy. , 2017, Immunotherapy.

[3]  J. Garcia,et al.  In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies. , 2017, The Journal of infectious diseases.

[4]  Y. Lévy,et al.  CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses , 2017, Nature.

[5]  C. Sabin,et al.  Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients , 2017, AIDS.

[6]  C. Wyatt.  Kidney Disease and HIV Infection. , 2017, Topics in antiviral medicine.

[7]  Anna Kula,et al.  Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir , 2017, AIDS.

[8]  J. Jaworski,et al.  Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success , 2017, Front. Immunol..

[9]  R. Koup,et al.  HIV antibodies for treatment of HIV infection , 2017, Immunological reviews.

[10]  D. Burton,et al.  Identification and specificity of broadly neutralizing antibodies against HIV , 2017, Immunological reviews.

[11]  A. Fauci,et al.  B‐cell responses to HIV infection , 2017, Immunological reviews.

[12]  A. Ciuffi,et al.  Single-virus tracking uncovers the missing link between HIV integration site location and viral gene expression , 2017, Nature Structural &Molecular Biology.

[13]  R. Siliciano,et al.  Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques , 2016, AIDS.

[14]  R. Hotchkiss,et al.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD‐1 or PD‐L1 expression and can be restored by antibodies targeting PD‐1 or PD‐L1 , 2016, Journal of leukocyte biology.

[15]  Abraham J. Kandathil,et al.  Are T cells the only HIV-1 reservoir? , 2016, Retrovirology.

[16]  C. Van Lint,et al.  Exploring the anatomical HIV reservoirs: role of the testicular tissue. , 2016, AIDS.

[17]  Andreas Meyerhans,et al.  Position effects influence HIV latency reversal , 2016, Nature Structural &Molecular Biology.

[18]  A. Rice,et al.  Cyclin-dependent kinases as therapeutic targets for HIV-1 infection , 2016, Expert opinion on therapeutic targets.

[19]  C. Van Lint,et al.  HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1 , 2016, Scientific Reports.

[20]  B. Haynes,et al.  Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection , 2016, Nature Reviews Drug Discovery.

[21]  M. Tolstrup,et al.  Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. , 2016, The lancet. HIV.

[22]  Steven G. Deeks,et al.  Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents , 2016, Open forum infectious diseases.

[23]  F. Forouzanfar,et al.  Targeting the Brain Reservoirs: Toward an HIV Cure , 2016, Front. Immunol..

[24]  Y. Shao,et al.  Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies , 2016, Front. Immunol..

[25]  J. Lifson,et al.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. , 2016, Immunity.

[26]  G. Hütter.  Stem cell transplantation in strategies for curing HIV/AIDS , 2016, AIDS Research and Therapy.

[27]  D. Burton,et al.  Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus , 2016, Science.

[28]  W. Alvord,et al.  Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques , 2016, Journal of Virology.

[29]  D. Nixon,et al.  T-cell therapies for HIV: Preclinical successes and current clinical strategies. , 2016, Cytotherapy.

[30]  A. Kaushik,et al.  Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. , 2016, Advanced drug delivery reviews.

[31]  R. Sékaly,et al.  The sooner the better: innate immunity as a path toward the HIV cure. , 2016, Current opinion in virology.

[32]  D. An,et al.  Stem cell-based therapies for HIV/AIDS. , 2016, Advanced drug delivery reviews.

[33]  J. Victor Garcia.  Humanized mice for HIV and AIDS research. , 2016, Current opinion in virology.

[34]  K. Khalili,et al.  Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study , 2016, Gene Therapy.

[35]  R. Bundschuh,et al.  Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9 , 2016, Scientific Reports.

[36]  Richard Jefferys,et al.  International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.

[37]  M. Churchill,et al.  Strategies to target HIV-1 in the central nervous system , 2016, Current opinion in HIV and AIDS.

[38]  L. Ndhlovu,et al.  Strategies to target non-T-cell HIV reservoirs , 2016, Current opinion in HIV and AIDS.

[39]  C. Van Lint,et al.  Preclinical shock strategies to reactivate latent HIV-1: an update , 2016, Current opinion in HIV and AIDS.

[40]  L. Trautmann.  Kill: boosting HIV-specific immune responses , 2016, Current opinion in HIV and AIDS.

[41]  C. Schwartz,et al.  Improving combination antiretroviral therapy by targeting HIV-1 gene transcription , 2016, Expert opinion on therapeutic targets.

[42]  J. Mellors,et al.  Which therapeutic strategy will achieve a cure for HIV-1? , 2016, Current opinion in virology.

[43]  G. Pantaleo,et al.  PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals , 2016, Nature Medicine.

[44]  P. Mallon,et al.  Protecting bone in long-term HIV positive patients receiving antiretrovirals , 2016, Expert review of anti-infective therapy.

[45]  A. Das,et al.  CRISPR/Cas9: a double-edged sword when used to combat HIV infection , 2016, Retrovirology.

[46]  P. Cannon,et al.  The clinical applications of genome editing in HIV. , 2016, Blood.

[47]  D. Hazuda,et al.  In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection , 2016, Retrovirology.

[48]  H. Gendelman,et al.  Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study , 2016, Gene Therapy.

[49]  G. Hütter.  HIV+ patients and HIV eradication – allogeneic transplantation , 2016, Expert review of hematology.

[50]  D. Leprince,et al.  Protein Kinase C-Mediated Phosphorylation of BCL11B at Serine 2 Negatively Regulates Its Interaction with NuRD Complexes during CD4+ T-Cell Activation , 2016, Molecular and Cellular Biology.

[51]  P. Gendron,et al.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. , 2016, Cell reports.

[52]  H. Mouquet,et al.  Elimination of HIV-1-infected cells by broadly neutralizing antibodies , 2016, Nature Communications.

[53]  D. Schaffer,et al.  CRISPR-mediated Activation of Latent HIV-1 Expression. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  M. Massanella,et al.  Residual inflammation and viral reservoirs: alliance against an HIV cure , 2016, Current opinion in HIV and AIDS.

[55]  G. Alter,et al.  NK Cells in HIV Disease , 2016, Current HIV/AIDS Reports.

[56]  D. Kučerová,et al.  Development of 5‘ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals , 2016, Clinical Epigenetics.

[57]  R. Siliciano,et al.  Molecular mechanisms of HIV latency. , 2016, The Journal of clinical investigation.

[58]  M. Tolstrup,et al.  Reversal of Latency as Part of a Cure for HIV-1. , 2016, Trends in microbiology.

[59]  M. Nussenzweig,et al.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. , 2016, The Journal of clinical investigation.

[60]  S. Valente,et al.  Didehydro-Cortistatin A: a new player in HIV-therapy? , 2016, Expert review of anti-infective therapy.

[61]  Emily B Hanhauser,et al.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV , 2016, bioRxiv.

[62]  Ben Berkhout,et al.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  H. Hatano,et al.  Post-Treatment Controllers: Role in HIV “Cure” Research , 2016, Current HIV/AIDS Reports.

[64]  R. Sanders,et al.  HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies , 2016, Expert review of vaccines.

[65]  Karen G. Dowell,et al.  Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control , 2016, PLoS pathogens.

[66]  Alan S. Perelson,et al.  Residual Viremia in Treated HIV+ Individuals , 2016, PLoS Comput. Biol..

[67]  Anna Kula,et al.  Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1 , 2015, EMBO molecular medicine.

[68]  J. Sodroski,et al.  Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells , 2015, Journal of Virology.

[69]  M. Mohan,et al.  Adipose Tissue: Sanctuary for HIV/SIV Persistence and Replication. , 2015, Trends in microbiology.

[70]  J. Church.  B Cell Follicle Sanctuary Permits Persistent Productive Simian Immunodeficiency Virus Infection in Elite Controllers , 2015, Pediatrics.

[71]  Won-Bin Young,et al.  CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs , 2015, Scientific Reports.

[72]  Adeolu Adegoke,et al.  Heteroclitic Peptides Increase Proliferation and Reduce Evidence of Human Immunodeficiency Virus-Specific CD8⁺ T Cell Dysfunction. , 2015, Viral immunology.

[73]  K. Allers,et al.  CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy. , 2015, Current opinion in virology.

[74]  C. Van Lint,et al.  Epigenetic control of HIV-1 post integration latency: implications for therapy , 2015, Clinical Epigenetics.

[75]  C. Rouzioux,et al.  Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection , 2015, PLoS pathogens.

[76]  G. Pantaleo,et al.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.

[77]  G. Silvestri,et al.  HIV therapeutic vaccines: moving towards a functional cure. , 2015, Current opinion in immunology.

[78]  S. Álvarez,et al.  Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism , 2015, Scientific Reports.

[79]  S. Lam,et al.  Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. , 2015, The Journal of infectious diseases.

[80]  L. Trautmann,et al.  The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency , 2015, mBio.

[81]  Arsène Burny,et al.  An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression , 2015, PLoS pathogens.

[82]  A. Samri,et al.  Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. , 2015, The Journal of antimicrobial chemotherapy.

[83]  S. Kent,et al.  Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells? , 2015, Front. Immunol..

[84]  K. Morris,et al.  The therapeutic application of CRISPR/Cas9 technologies for HIV , 2015, Expert opinion on biological therapy.

[85]  John R Mascola,et al.  Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.

[86]  Y. Pacheco,et al.  Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. , 2015, Antiviral research.

[87]  Jessica M Conway,et al.  Post-treatment control of HIV infection , 2015, Proceedings of the National Academy of Sciences.

[88]  V. Valcour,et al.  CNS reservoirs for HIV: implications for eradication , 2015, Journal of virus eradication.

[89]  H. Hatano,et al.  Clinical outcomes and antiretroviral therapy in ‘elite’ controllers: a review of the literature , 2015, Journal of virus eradication.

[90]  Mary Jane Drake,et al.  Application of gene-editing technologies to HIV-1. , 2015, Current opinion in HIV and AIDS.

[91]  Igor M. Rouzine,et al.  A Hardwired HIV Latency Program , 2015, Cell.

[92]  Ariel D. Weinberger,et al.  An Evolutionary Role for HIV Latency in Enhancing Viral Transmission , 2015, Cell.

[93]  K. Khalili,et al.  Genome editing strategies: potential tools for eradicating HIV-1/AIDS , 2015, Journal of NeuroVirology.

[94]  E. Shankar,et al.  Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options , 2015, Retrovirology.

[95]  H. Hatano,et al.  Elite control of HIV: is this the right model for a functional cure? , 2015, Trends in microbiology.

[96]  G. Jiang,et al.  Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. , 2015, AIDS research and human retroviruses.

[97]  R. Siliciano,et al.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.

[98]  Richard D Moore,et al.  Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. , 2014, The Journal of infectious diseases.

[99]  D. Richman,et al.  HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. , 2014, The Journal of infectious diseases.

[100]  J. Garcia,et al.  Humanized mouse models for HIV-1 infection of the CNS , 2014, Journal of NeuroVirology.

[101]  D. Margolis,et al.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen , 2014, Nature Reviews Microbiology.

[102]  J. Reece,et al.  Modeling the Timing of Antilatency Drug Administration during HIV Treatment , 2014, Journal of Virology.

[103]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[104]  L. Weinberger,et al.  Stochastic variability in HIV affects viral eradication , 2014, Proceedings of the National Academy of Sciences.

[105]  Emily B Hanhauser,et al.  Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation , 2014, Annals of Internal Medicine.

[106]  M. Nussenzweig,et al.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.

[107]  D. Schadendorf,et al.  Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. , 2014, The New England journal of medicine.

[108]  T. Chun,et al.  Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir , 2014, Proceedings of the National Academy of Sciences.

[109]  A. Tanuri,et al.  Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. , 2014, Virology.

[110]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[111]  Jinyan Liu,et al.  Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.

[112]  C. Schwartz,et al.  The Many Lives of CTIP2: From AIDS to Cancer and Cardiac Hypertrophy , 2014, Journal of cellular physiology.

[113]  Kholoud Porter,et al.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy , 2014, AIDS.

[114]  J. Karn,et al.  Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. , 2014, Virology.

[115]  Feng Fu,et al.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 , 2014, Proceedings of the National Academy of Sciences.

[116]  C. Van Lint,et al.  HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters , 2014, Nucleic acids research.

[117]  Carlos A Ramos,et al.  CD19-CAR Trials , 2014, Cancer journal.

[118]  H. Kiem,et al.  Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  P. Mallon.  Impact of nucleoside reverse transcriptase inhibitors on coronary heart disease. , 2014, Reviews in cardiovascular medicine.

[120]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[121]  L. Al-Harthi,et al.  Epigenetic Regulation of HIV-1 Latency in Astrocytes , 2013, Journal of Virology.

[122]  Ravindra K. Gupta,et al.  Macrophages: the neglected barrier to eradication. , 2013, Current opinion in infectious diseases.

[123]  Eric Verdin,et al.  An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients , 2013, PLoS pathogens.

[124]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[125]  Kimberly R. Jordan,et al.  Improving Antigenic Peptide Vaccines for Cancer Immunotherapy Using a Dominant Tumor-specific T Cell Receptor* , 2013, The Journal of Biological Chemistry.

[126]  Mary K. Lewinski,et al.  HIV latency and integration site placement in five cell-based models , 2013, Retrovirology.

[127]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[128]  Felipe García,et al.  Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. , 2013, AIDS research and human retroviruses.

[129]  F. Dequiedt,et al.  CTIP2 is a negative regulator of P-TEFb , 2013, Proceedings of the National Academy of Sciences.

[130]  C. Van Lint,et al.  HIV-1 transcription and latency: an update , 2013, Retrovirology.

[131]  Alessandro Marcello,et al.  HIV-1 transcription and latency: an update , 2013, Retrovirology.

[132]  B. Walker,et al.  Unravelling the mechanisms of durable control of HIV-1 , 2013, Nature Reviews Immunology.

[133]  Michael S. Pepper,et al.  C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection☆ , 2013, Applied & translational genomics.

[134]  C. Rouzioux,et al.  Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2013, JAMA internal medicine.

[135]  E. Nicastri,et al.  Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment , 2013, AIDS.

[136]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[137]  G. Pantaleo,et al.  Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.

[138]  C. Tural,et al.  Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy , 2013, AIDS.

[139]  D. Begley,et al.  Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[140]  Qiang Zhou,et al.  The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation , 2012, Nucleic acids research.

[141]  B. Rodés,et al.  Long-Term Nonprogressor and Elite Controller Patients Who Control Viremia Have a Higher Percentage of Methylation in Their HIV-1 Proviral Promoters than Aviremic Patients Receiving Highly Active Antiretroviral Therapy , 2012, Journal of Virology.

[142]  B. Peterlin,et al.  Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein* , 2012, The Journal of Biological Chemistry.

[143]  T. Chun,et al.  Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. , 2012, The Journal of infectious diseases.

[144]  J. Gatot,et al.  Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients , 2012, AIDS.

[145]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[146]  B. Peterlin,et al.  PKC phosphorylates HEXIM1 and regulates P-TEFb activity , 2012, Nucleic acids research.

[147]  E. Verdin,et al.  HIV latency: experimental systems and molecular models. , 2012, FEMS microbiology reviews.

[148]  T. Chun,et al.  Paucity of HIV DNA Methylation in Latently Infected, Resting CD4+ T Cells from Infected Individuals Receiving Antiretroviral Therapy , 2012, Journal of Virology.

[149]  C. Schwartz,et al.  Achieving a cure for HIV infection: do we have reasons to be optimistic? , 2012, The Journal of antimicrobial chemotherapy.

[150]  C. Van Lint,et al.  LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing , 2011, Nucleic acids research.

[151]  J. Church.  Evidence for the Cure of HIV Infection by CCR5δ32/Δ32 Stem Cell Transplantation , 2011, Pediatrics.

[152]  D. Montefiori,et al.  Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion , 2011, PLoS pathogens.

[153]  A. Bergamaschi,et al.  Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. , 2011, Blood.

[154]  B. Autran,et al.  Elite controllers as a model of functional cure , 2011, Current opinion in HIV and AIDS.

[155]  O. Lambotte,et al.  Epidemiology and clinical characteristics of elite controllers , 2011, Current opinion in HIV and AIDS.

[156]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[157]  L. Agosto,et al.  HIV reservoirs and latency models. , 2011, Virology.

[158]  J. Clements,et al.  Eradication of HIV from the brain: reasons for pause. , 2011, AIDS.

[159]  S. Migueles,et al.  Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART , 2011, PLoS pathogens.

[160]  O. Pybus,et al.  B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection , 2010, Nature communications.

[161]  C. Van Lint,et al.  CpG methylation controls reactivation of HIV from latency , 2010, Retrovirology.

[162]  A. Burny,et al.  DNA Cytosine Methylation in the Bovine Leukemia Virus Promoter Is Associated with Latency in a Lymphoma-derived B-cell Line , 2010, The Journal of Biological Chemistry.

[163]  C. Van Lint,et al.  HIV‐1 regulation of latency in the monocyte‐macrophage lineage and in CD4+ T lymphocytes , 2010, Journal of leukocyte biology.

[164]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[165]  Alan S. Perelson,et al.  Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy , 2009, PLoS Comput. Biol..

[166]  D. Aunis,et al.  p21WAF1 gene promoter is epigenetically silenced by CTIP2 and SUV39H1 , 2009, Oncogene.

[167]  Arsène Burny,et al.  Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection , 2009, PloS one.

[168]  E. Verdin,et al.  Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation , 2009, PLoS pathogens.

[169]  A. Phillips,et al.  The role of HIV in serious diseases other than AIDS , 2008, AIDS.

[170]  C. June,et al.  Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor , 2008, Nature Medicine.

[171]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[172]  Jeffrey N. Martin,et al.  Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy , 2008, Journal of Virology.

[173]  Sri H. Ramarathinam,et al.  Prevention of Cytotoxic T Cell Escape Using a Heteroclitic Subdominant Viral T Cell Determinant , 2008, PLoS pathogens.

[174]  B. Walker,et al.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. , 2007, Immunity.

[175]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[176]  F. Dequiedt,et al.  Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.

[177]  A. Knezevich,et al.  Suv39H1 and HP1γ are responsible for chromatin‐mediated HIV‐1 transcriptional silencing and post‐integration latency , 2007, The EMBO journal.

[178]  A. Rice,et al.  Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells , 2006, Retrovirology.

[179]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[180]  A. Sharpe,et al.  T-cell costimulation--biology, therapeutic potential, and challenges. , 2006, The New England journal of medicine.

[181]  Q. Lin,et al.  BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter , 2005, Oncogene.

[182]  Y. Becker.  The Molecular Mechanism of Human Resistance to HIV-1 Infectionin Persistently Infected Individuals—A Review, Hypothesis and Implications , 2005, Virus Genes.

[183]  C. Van Lint,et al.  COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells , 2005, Nucleic acids research.

[184]  M. Sporn,et al.  Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation , 2005, Journal of Virology.

[185]  C. Wijmenga,et al.  The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes , 2003, Nature.

[186]  D. Aunis,et al.  Recruitment of Tat to Heterochromatin Protein HP1 via Interaction with CTIP2 Inhibits Human Immunodeficiency Virus Type 1 Replication in Microglial Cells , 2003, Journal of Virology.

[187]  C. Van Lint,et al.  Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. , 2002, Biochemical pharmacology.

[188]  J. van Lunzen,et al.  Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial) , 2002, AIDS.

[189]  B. Peterlin,et al.  NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II , 2001 .

[190]  H. Schuitemaker,et al.  OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion , 2001, Journal of Clinical Immunology.

[191]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[192]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[193]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[194]  M. Clementi,et al.  Analysis of HIV‐1 load in blood, semen and saliva: evidence for different viral compartments in a cross‐sectional and longitudinal study , 1996, AIDS.

[195]  C. Van Lint,et al.  Transcriptional activation and chromatin remodeling of the HIV‐1 promoter in response to histone acetylation. , 1996, The EMBO journal.

[196]  K. Krogsgaard,et al.  Combined eff ect of Vacc-4 x , recombinant human granulocyte macrophage colony-stimulating factor vaccination , and romidepsin on the HIV-1 reservoir ( REDUC ) : a single-arm , phase 1 B / 2 A trial , 2016 .

[197]  S. Valente,et al.  Targeting HIV transcription: the quest for a functional cure. , 2015, Current topics in microbiology and immunology.

[198]  S. Evers,et al.  CSF Penetration by Antiretroviral Drugs , 2012, CNS Drugs.

[199]  D. Aunis,et al.  gene promoter is epigenetically silenced by CTIP 2 and SUV 39 H 1 , 2012 .

[200]  E. Thiel,et al.  Long-Term Control of HIV by CCR 5 Delta 32 / Delta 32 Stem-Cell Transplantation , 2009 .

[201]  B. Peterlin,et al.  NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. , 2001, Molecular cell.

[202]  Eyton,et al.  A CONTROLLED TRIAL OF TWO NUCLEOSIDE ANALOGUES PLUS INDINAVIR IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND CD4 CELL COUNTS OF 200 PER CUBIC MILLIMETER OR LESS , 2000 .